Sanofi-Aventis SA has announced that it has begun the clinical trials of a purported vaccine for the H7N1 bird flu strain, a different but equally ferocious strain that could spark off a potential pandemic.
60 adults at the Haukeland University Hospital in Bergen, Norway will be subjects of the clinical trials to be conducted by Sanofi Pasteur. The H5N1 strain of bird flu virus had hogged the limelight and earlier research for vaccines had centered on this strain. Now, Scientists are contributing their mite to build a vaccine for a variation in the strain, so that they are geared up to tackle even a deadly outbreak.
You May Also Like